You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Fig. 3

The PD-1 + CD137+ CD8+ T-cells increase with the addition of αCSF-1R to GVAX therapy and αPD-1. Liver metastatic KPC tumor-bearing mice were sacrificed on day 14 after receiving treatment, and flow cytometry analysis was performed on the isolated tumor infiltrating immune cells. The percentage of PD-1 + CD137+ cells within the (a) CD45 + CD4+ and (d) CD45 + CD8+ T-cell populations. The proportion of cells expressing CD137 amongst (b) CD45 + CD4 + PD-1+ and (e) CD45 + CD8 + PD-1+ T-cells. The number of (c) CD45 + CD4 + PD-1 + CD137+ and (f) CD45 + CD8+ PD-1 + CD137+ T-cells. N = 3 for each treatment group, and the isolated immune cells from mice from the same treatment group were pooled and measured in triplicates. *p < 0.05; **p < 0.01; ***p < 0.001; NS, non-significant

Back to article page